FI
SGMO

Fosun International’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Fosun International’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-62,808
Closed -$663K – 283
2019
Q2 		$663K Buy
+62,808
New +$668K 0.04% 203

Other funds holding SGMO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fosun International's SGMO Position: Q3 2019 in Review

Fosun International sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2019, closing a stake of 62,808 shares — an estimated $663K sold.

Fosun International first reported a position in SGMO in Q2 2019 and held it in 1 quarter. The position peaked at $663K in Q2 2019. 184 funds tracked by Wall St. Rank hold SGMO as of Q3 2019.

  • Fosun International reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 62,808 SANGAMO THERAPEUTICS INC shares in Q3 2019, an estimated $663K.
  • Fosun International first reported a position in SANGAMO THERAPEUTICS INC in Q2 2019 and held it in 1 quarter.
  • Fosun International's SANGAMO THERAPEUTICS INC position peaked at $663K in Q2 2019.
  • 184 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.